Gilead Sciences Inc.

Organisation

333 Lakeside Drive, Foster City, CA, United States, 94404

Headquarters

17000

Employees

Health Technology

Industry

Daniel O'Day

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Price

Target

Gilead Sciences Inc. (GILD) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Gilead Sciences Inc. (GILD) share price will touch around $157.43 in next 12-months.

Currently 38 wall-street analysts regularly analyze the financials of Gilead Sciences Inc. on a frequent basis to provide recommendations along with target share price. 38 analysts offering 12-month price forecasts for Gilead Sciences Inc. (GILD) have a share price target of $157.43. This median of share price forecast represents a 11.43% upside from the latest price of $141.28 as on 19.03.26.

Gilead Sciences Inc. (GILD) Share Price Forecast

Home

US Stocks

Gilead Sciences Inc. (GILD)

Gilead Sciences Inc. Stock Forecast

Gilead Sciences Inc. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Gilead Sciences Inc. (GILD): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Gilead Sciences Inc.'s share price and its median forecast price. As on 19.03.26, the difference is -6.08%

Gilead Sciences Inc. Forecast and Target Price

Gilead Sciences Inc. (GILD) Share Price Forecast

Gilead Sciences Inc. (GILD) Price vs Consensus Price Target

Gilead Sciences Inc. (GILD) Share Price Forecast v/s Share Price Today

Gilead Sciences Inc. (GILD): Difference between Current Price & Median Forecasted Price

Gilead Sciences Inc. (GILD) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price